ANNUAL

REPORT

DRIVEN TO

MAKE A

DIFFERENCE

Through the dedication and hard work of over 1,100 employees, we continued to deliver flexible, single-use bioprocessing solutions to customers around the globe in 2020. Our focus on innovation continued to differentiate us in the bioprocessing market and helped to deliver strong financial performance. This 2020 annual report is dedicated to our unwavering team, driven to make a difference by supporting advances in biologics that are improving the lives of patients worldwide.

BUSINESS HIGHLIGHTS 2020

22

$366M

36%

$46M

reported

revenue growth,

revenue from

revenue

29% organic growth

COVID-19

related programs

$54M

55%

$717M

revenue from cell

increase in

cash and cash

& gene therapy

adjusted fully

equivalents at

accounts

diluted EPS

year end

3

3

115K

key acquisitions

total number

increase in

to expand our

of new product

square footage

Systems strategy

launches

of Repligen sites

worldwide

3

4

Attachments

  • Original document
  • Permalink

Disclaimer

Repligen Corporation published this content on 12 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 May 2021 16:10:05 UTC.